Editas Medicine (EDIT) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prothena (PRTA) has outperformed Editas Medicine (EDIT) over the past year, losing 16.6% versus a loss of 30.0%. Over five years, PRTA leads with a -86.6% price change compared with -92.8% for EDIT. Prothena is the larger company by market cap ($435.3 million vs $422.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | PRTA |
|---|---|---|
| Share price | $2.75 | $8.48 |
| Market cap | $422.35M | $435.34M |
| 1-day change | +0.73% | +5.74% |
| YTD return | +34.15% | -11.20% |
| 1-year return | -30.03% | -16.62% |
| 5-year return | -92.77% | -86.64% |
| EPS (TTM) | $-0.68 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.33 | $11.80 |
| 52-week low | $1.66 | $7.73 |
| Distance from 52-week high | -36.49% | -28.14% |
| Analyst consensus | buy | none |
| Avg. price target upside | +114.55% | +152.36% |
| Average volume | 2.47M | 482.01K |
| Shares outstanding | 153.58M | 51.34M |
| Employees | 87 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRTA has outperformed EDIT by 13.4 percentage points over the past year.
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
EDIT vs PRTA FAQ
Which is bigger, Editas Medicine or Prothena?
Prothena (PRTA) is larger, with a market capitalization of $435.34M compared with $422.35M for Editas Medicine (EDIT).
Which stock has performed better over the past year, EDIT or PRTA?
PRTA returned -16.62% over the past 12 months, compared with -30.03% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and Prothena in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Editas Medicine and Biotechnology: Pharmaceutical Preparations for Prothena.